Huami Corp Invests $5 Million in Hyperfine Research D Round

February 10, 2021

Huami Corp. announced that it has invested $5 million in Hyperfine Research’s D round of funding, which closed on February 3, 2021. Funds to support the accelerated application of disruptive MRI technology.

Huami Corporate mission is to connect health with technology, developing both consumer and industrial health technologies. The company believes its miniaturization engineering expertise dovetails with efforts to miniaturize medical imaging technology which can disrupt the locations, applications, and costs of medical imaging.

Hyperfine Research is pioneering MRI imaging with its portable Swoop system, which received FDA 510(K) clearance in August of 2020.

“In the same way that new depth and granularity of data from wearable devices has changed health population management, we see the miniaturization of imaging technology changing the places and speed at which clinicians can evaluate patients,” said Huami’s chief operating officer, Mike Yeung. “We are excited to participate with Hyperfine in support of their mission.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Noze states the grant will fund a groundbreaking clinical study aimed at detecting TB in high-burden countries, using the company's DiagNoze® — a handheld breathalyzer designed for the real-time detection and screening of various medical conditions, including infectious diseases such as TB.
Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version